Lapatinib: new opportunities for management of breast cancer

References

• JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin200959422524919474385
   PubMed Web of Science ®Google Scholar
• ChuIBlackwellKChenSSlingerlandJThe dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancerCancer Res2005651182515665275
   PubMed Web of Science ®Google Scholar
• TsutsuiSOhnoSMurakamiSHachitandaYOdaSPrognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancerBreast Cancer Res Treat2002711677511859875
   PubMed Web of Science ®Google Scholar
• NicholsonSWrightCSainsburyJREpidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failureJ Steroid Biochem Mol Biol19903768118142285594
   PubMed Web of Science ®Google Scholar
• AgrawalAGutteridgeEGeeJMNicholsonRIRobertsonJFOverview of tyrosine kinase inhibitors in clinical breast cancerEndocr Relat Cancer200512Suppl 1S135S14416113090
   PubMed Web of Science ®Google Scholar
• RuschVBaselgaJCordoncardoCDifferential expression of the epidermal growth-factor receptor and its ligands in primary nonsmall cell lung cancers and adjacent benign lungCancer Res19935310237923857683573
   PubMed Web of Science ®Google Scholar
• SelvaggiGNovelloSTorriVEpidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancerAnn Oncol2004151283214679115
   PubMed Web of Science ®Google Scholar
• OnnACorreaAMGilcreaseMSynchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancerClin Cancer Res2004101 Pt 113614314734462
   PubMed Web of Science ®Google Scholar
• OhtsukaKOhnishiHFuruyashikiGClinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinomaJ Thorac Oncol20061878779517409961
   PubMed Web of Science ®Google Scholar
• BaselgaJSwainSMNovel anticancer targets: Revisiting ERBB2 and discovering ERBB3Nat Rev Cancer20099746347519536107
   PubMed Web of Science ®Google Scholar
• PrickettTDAgrawalNSWeiXAnalysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4Nat Genet200941101127113219718025
   PubMed Web of Science ®Google Scholar
• GadellaTW JrJovinTMOligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activationJ Cell Biol19951296154315587790353
   PubMed Web of Science ®Google Scholar
• MorikiTMaruyamaHMaruyamaINActivation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domainJ Mol Biol200131151011102611531336
   PubMed Web of Science ®Google Scholar
• SchoeberlBFaberACLiDAn ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationCancer Res20107062485249420215504
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol20012212713711252954
   PubMed Web of Science ®Google Scholar
• PressMFSlamonDJFlomKJParkJZhouJYBernsteinLEvaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimensJ Clin Oncol200220143095310512118023
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerArch Pathol Lab Med20071311184319548375
   PubMed Web of Science ®Google Scholar
• SauterGLeeJBartlettJMSlamonDJPressMFGuidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerationsJ Clin Oncol20092781323133319204209
   PubMed Web of Science ®Google Scholar
• SpectorNLBlackwellKLUnderstanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol200927345838584719884552
   PubMed Web of Science ®Google Scholar
• PegramMHsuSLewisGInhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene199918132241225110327070
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol200220371972611821453
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• LanKHLuCHYuDMechanisms of trastuzumab resistance and their clinical implicationsAnn N Y Acad Sci20051059707516382045
   PubMed Web of Science ®Google Scholar
• FaneyteIFPeterseJLvanTHPredicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvementClin Cancer Res200410134457446315240537
   PubMed Web of Science ®Google Scholar
• MontemurroFDonadioMClavarezzaMOutcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapyOncologist200611431832416614227
   PubMed Web of Science ®Google Scholar
• Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateCancer Res200868229280929019010901
   PubMed Web of Science ®Google Scholar
• AgusDBGordonMSTaylorCPhase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerJ Clin Oncol200523112534254315699478
   PubMed Web of Science ®Google Scholar
• GianniLLladoABianchiGOpen-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancerJ Clin Oncol20102871131113720124183
   PubMed Web of Science ®Google Scholar
• GelmonKAFurnoleauPVermaSResults of a Phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapyJ Clin Oncol20082647S1026
   Web of Science ®Google Scholar
• CitriAYardenYEGF-ERBB signalling: Towards the systems levelNat Rev Mol Cell Biol20067750551616829981
   PubMed Web of Science ®Google Scholar
• Tykerb® (Lapatinib, Package insert)Research Triangle Park NCGlaxoSmithKline2010
   Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• SpectorNLXiaWBurrisH IIIStudy of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignanciesJ Clin Oncol200523112502251215684311
   PubMed Web of Science ®Google Scholar
• LackeyKELessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitorCurr Top Med Chem20066543546016719802
   PubMed Web of Science ®Google Scholar
• WoodERTruesdaleATMcDonaldOBA unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cellsCancer Res200464186652665915374980
   PubMed Web of Science ®Google Scholar
• AnidoJScaltritiMBech SerraJJBiosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translationEMBO J200625133234324416794579
   PubMed Web of Science ®Google Scholar
• PupaSMMenardSMorelliDPozziBDePGColnaghiMIThe extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavageOncogene1993811291729238105438
   PubMed Web of Science ®Google Scholar
• ScaltritiMRojoFOcanaAExpression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerJ Natl Cancer Inst200799862863817440164
   PubMed Web of Science ®Google Scholar
• ChristiansonTADohertyJKLinYJNH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancerCancer Res19985822512351299823322
   PubMed Web of Science ®Google Scholar
• MolinaMASaezRRamseyEENH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancerClin Cancer Res20028234735311839648
   PubMed Web of Science ®Google Scholar
• BramwellVHDoigGSTuckABChanges over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancerBreast Cancer Res Treat2009114350351118437556
   PubMed Web of Science ®Google Scholar
• AliSMCarneyWPEstevaFJSerum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancerCancer200811361294130118661530
   PubMed Web of Science ®Google Scholar
• NunesRAHarrisLNThe HER2 extracellular domain as a prognostic and predictive factor in breast cancerClin Breast Cancer20023212513512123536
   PubMedGoogle Scholar
• MazouniCHallABroglioKKinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapyCancer2007109349650117149760
   PubMed Web of Science ®Google Scholar
• SperindeJJinXBanerjeeJQuantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patientsClin Cancer Res201016164226423520664024
   PubMed Web of Science ®Google Scholar
• SaezRMolinaMARamseyEEp95HER-2 predicts worse outcome in patients with HER-2-positive breast cancerClin Cancer Res200612242443116428482
   PubMed Web of Science ®Google Scholar
• RusnakDWLackeyKAffleckKThe effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivoMol Cancer Ther200112859412467226
   PubMed Web of Science ®Google Scholar
• KonecnyGEPegramMDVenkatesanNActivity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsCancer Res20066631630163916452222
   PubMed Web of Science ®Google Scholar
• BenceAKAndersonEBHalepotaMAPhase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjectsInvest New Drugs2005231394915528979
   PubMed Web of Science ®Google Scholar
• BurrisHA IIIHurwitzHIDeesECPhase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasJ Clin Oncol200523235305531315955900
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationApproval package for Application number NDA 22-0592010
   Google Scholar
• MedinaPJGoodinSLapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinasesClin Ther20083081426144718803986
   PubMed Web of Science ®Google Scholar
• MoyBGossPELapatinib-associated toxicity and practical management recommendationsOncologist200712775676517673607
   PubMed Web of Science ®Google Scholar
• BursteinHJStornioloAMFrancoSA phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancerAnn Oncol20081961068107418283035
   PubMed Web of Science ®Google Scholar
• BlackwellKLBursteinHJPegramMDetermining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancerJ Clin Oncol200523Suppl 16193s
   Web of Science ®Google Scholar
• IwataHToiMFujiwaraYPhase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer Presented at: San Antonio Breast Cancer Symposium San Antonio, TX Dec 14–17, 2006
   Google Scholar
• GomezHLDovalDCChavezMAEfficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancerJ Clin Oncol200826182999300518458039
   PubMed Web of Science ®Google Scholar
• di LeoAGomezHAzizZLapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patientsJ Clin Oncol200725Suppl34s
   Google Scholar
• NicholsonRIGeeJMHarperMEEGFR and cancer prognosisEur J Cancer200137Suppl 4S9S1511597399
   PubMed Web of Science ®Google Scholar
• LiptonAAliSMLeitzelKSerum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifenJ Clin Oncol200321101967197212743150
   PubMed Web of Science ®Google Scholar
• ArpinoGWiechmannLOsborneCKSchiffRCrosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistanceEndocr Rev200829221723318216219
   PubMed Web of Science ®Google Scholar
• HurtadoAHolmesKAGeistlingerTRRegulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifenNature2008456722266366619005469
   PubMed Web of Science ®Google Scholar
• YangZBarnesCJKumarRHuman epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cellsClin Cancer Res200410113621362815173068
   PubMed Web of Science ®Google Scholar
• BenzCCScottGKSarupJCEstrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neuBreast Cancer Res Treat199224285958095168
   PubMed Web of Science ®Google Scholar
• PietrasRJArboledaJReeseDMHER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cellsOncogene19951012243524467784095
   PubMed Web of Science ®Google Scholar
• ShinIMillerTArteagaCLErbB receptor signaling and therapeutic resistance to aromatase inhibitorsClin Cancer Res2006123 Pt 2S1008S1012
   Web of Science ®Google Scholar
• MackeyJRKaufmanBClemensMTrastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancerBreast Cancer Res Treat2006100Suppl 1S5
   Google Scholar
• JohnstonSPippenJ JrPivotXLapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerJ Clin Oncol200927335538554619786658
   PubMed Web of Science ®Google Scholar
• WaknineYFDA approves lapatinib/letrozole combination for advanced breast cancerMedscape Medical News2010 Available from: http://www.medscape.com/viewarticle/716263Accessed 2010 Sep 15
   Google Scholar
• StornioloAMPegramMDOvermoyerBPhase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerJ Clin Oncol200826203317332318490651
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJBlackwellKLBursteinHJA randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapyJ Clin Oncol200826No 15S1015
   Web of Science ®Google Scholar
• BlackwellKBursteinHLedgeGUpdated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapyCancer Res200969Suppl 24 Abstr 61
   Web of Science ®Google Scholar
• LowJABermanAWSteinbergSMDanforthDNLippmanMESwainSMLong-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapyJ Clin Oncol200422204067407415483018
   PubMed Web of Science ®Google Scholar
• ChangSParkerSLPhamTBuzdarAUHurstingSDInflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992Cancer19988212236623729635529
   PubMed Web of Science ®Google Scholar
• BlackwellKLPegramMDTan-ChiuESingle-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimensAnn Oncol20092061026103119179558
   PubMed Web of Science ®Google Scholar
• JohnstonSTrudeauMKaufmanBPhase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapyJ Clin Oncol20082671066107218212337
   PubMed Web of Science ®Google Scholar
• SpectorNLBlackwellKHurleyJEGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of responseProc Am Soc Clin Oncol2006243S Abstr 502
   Google Scholar
• KaufmanBTrudeauMAwadaALapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: Final results and survival of the expanded HER2+ cohort in EGF103009, a phase II studyLancet Oncol200910658158819394894
   PubMed Web of Science ®Google Scholar
• CristofanilliMKrishnamurthySGuerraLA phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC)Breast Cancer Res Treat2006100Suppl 1S5
   Google Scholar
• DiStefanoAYongYYHortobagyiGNBlumenscheinGRThe natural history of breast cancer patients with brain metastasesCancer197944519131918498057
   PubMed Web of Science ®Google Scholar
• StewartJFKingRJSextonSAMillisRRRubensRDHaywardJLOestrogen receptors, sites of metastatic disease and survival in recurrent breast cancerEur J Cancer19811744494537308254
   PubMed Web of Science ®Google Scholar
• BriaECupponeFFornierMCardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: The dark side of the moon? A meta-analysis of the randomized trialsBreast Cancer Res Treat2008109223123917638068
   PubMed Web of Science ®Google Scholar
• LinNUBellonJRWinerEPCNS metastases in breast cancerJ Clin Oncol200422173608361715337811
   PubMed Web of Science ®Google Scholar
• LinNUCareyLALiuMCPhase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol200826121993199918421051
   PubMed Web of Science ®Google Scholar
• TevaarwerkAJKolesarJMLapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancerClin Ther200931Pt 22332234820110044
   PubMed Web of Science ®Google Scholar
• Tan-ChiuEYothersGRomondEAssessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31J Clin Oncol200523317811781916258083
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNEExploratory analysis from NCCTG N9831: Do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy?Breast Cancer Res Treat200594Suppl 1S96
   Google Scholar
• PerezEAKoehlerMByrneJPrestonAJRappoldEEwerMSCardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trialsMayo Clin Proc200883667968618533085
   PubMed Web of Science ®Google Scholar
• Red Book 2009: Pharmacy’s Fundamental Reference113th ed2009
   Google Scholar